尤瑞克林联合依达拉奉治疗急性脑梗死的临床疗效  

Clinical efficacy of ureklin with daravong in the treatment of acute cerebral infarction

作　　者：杨雪山[1] 刘磊[1] 朱龙 YANG Xue-shan;LIU Lei;ZHU Long(Taihe Country Hospitai of Traditional Chinese Medicine,Fuyang,Anhui 236600,China)

机构地区：[1]太和县中医院,安徽阜阳236600

出　　处：《中国国境卫生检疫杂志》2021年第S01期121-122,共2页Chinese Journal of Frontier Health and Quarantine

摘　　要：目的探讨尤瑞克林联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法选取2016—2021年本院收治的急性脑梗死患者80例,依据治疗方法分为尤瑞克林联合依达拉奉组(联合治疗组)、单独依达拉奉组(单独治疗组),每组各40例。结果联合治疗组患者治疗总有效率为95.0%(38/40),高于单独治疗组的77.5%(31/40)(P<0.05)。联合治疗组患者的不良反应发生率为5.0%(2/40),低于单独治疗组的32.5%(13/40)(P<0.05)。结论在急性脑梗死治疗中,与单独依达拉奉治疗相比,尤瑞克林联合依达拉奉治疗的临床疗效及安全性较高。Objective To investigate the clinical efficacy and safety of urinary kallidinogenase combined with edaravone in the treatment of acute cerebral infarction.Methods 80 cases of patients with acute cerebral infarction in our hospital from 2016 to 2021 were selected retrospectively.According to the treatment methods,they were divided into two groups,Urinary Kallidinogenase combined with edaravone treatment group(combined treatment group)and edaravone alone treatment group(separate treatment group),with 40 cases in each group.Results The total effective rate of the combined treatment group was 95.0%(38/40),which was higher than 77.5%(31/40)of the single treatment group(P<0.05).The incidence of adverse reactions in the combined treatment group was 5.0%(2/40),which was lower than 32.5%(13/40)in the single treatment group(P<0.05).Conclusion The clinical efficacy and safety of urinary kallidinogenase combined with edaravone in the treatment of acute cerebral infarction is higher than that of edaravone alone.

关 键 词：急性脑梗死 尤瑞克林 依达拉奉 

分 类 号：R183[医药卫生—流行病学]